EUVIMEDEUVIMED entdecken
Metaanalyse

Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis

Zengyun Qiao, Enbo Wang, Boyang Bao, Xiaodong Tan, Hailong Chen, Dong Wang, Liu Yuan

Laboratory Medicine · 04.09.2024 · 55 (5) · 543-552

DOI: 10.1093/labmed/lmae013 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Laboratory Medicine, online erschienen am 12.03.2024. Verfasst von Zengyun Qiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Dalian Municipal Central Hospital, Dalian, China. Hauptthemen laut MEDLINE: Glypicans, Pancreatic Neoplasms, Exosomes, Biomarkers, Tumor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer (PC) is usually detected in the advanced stages. Liquid biopsy has become a revolutionary strategy for cancer diagnosis and prognosis prediction. This study aims to investigate the diagnostic and prognostic value of circulating exosomal glypican-1 (GPC-1) in PC.

Methods

We systematically searched relevant studies. For diagnostic accuracy, pooled sensitivity and specificity and the area under the summary receiver operating characteristic curve (AUC) were calculated. Regarding prognostic value, hazard ratios (HRs) and 95% CIs for overall survival (OS) were summarized by using a random-effects model.

Results

We found 8 studies that examined the diagnostic value of circulating exosomal GPC-1 in PC, and 3 studies that investigated its prognostic value. Pooled sensitivity and specificity were 0.88 (95% CI, 0.65-0.97) and 0.86 (95% CI, 0.72-0.94). The AUC was 0.93 (95% CI, 0.90-0.95). Prognostic analysis showed that higher levels of circulating exosomal GPC-1 were associated with poorer OS in PC patients, and the combined HR for OS was 4.59 (random-effects model, 95% CI = 1.17-18.03, P = .022). The results of both studies were robust and neither had publication bias.

Conclusion

Circulating exosomal GPC-1 may be used as a diagnostic and prognostic biomarker for PC. However, this result needs to be validated by further research using a larger sample size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlypicansPancreatic NeoplasmsExosomesBiomarkers, TumorHumansPrognosisSensitivity and SpecificitySurvival AnalysisROC Curve

Stichwörter der Autor:innen

circulating exosomal GPC-1diagnostic accuracyliquid biopsymeta-analysispancreatic cancerprognostic value

Substanzen

GlypicansBiomarkers, TumorGPC1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Dalian Municipal Central Hospital, Dalian, China.
  • China Medical University, Shenyang, China.
  • Dalian Medical University, Dalian, China.

Zitieren

APA

Qiao, Z., Wang, E., Bao, B., Tan, X., Chen, H., Wang, D., & Yuan, L. (2024). Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis. Laboratory Medicine, 55(5), 543-552. https://doi.org/10.1093/labmed/lmae013

Vancouver

Qiao Z, Wang E, Bao B, Tan X, Chen H, Wang D, et al. Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis. Laboratory Medicine. 2024;55(5):543-552. doi:10.1093/labmed/lmae013

BibTeX
@article{Qiao2024,
  author = {Qiao, Zengyun and Wang, Enbo and Bao, Boyang and Tan, Xiaodong and Chen, Hailong and Wang, Dong and Yuan, Liu},
  title = {Diagnostic and prognostic value of circulating exosomal glypican-1 in pancreatic cancer: a meta-analysis},
  journal = {Laboratory Medicine},
  year = {2024},
  volume = {55},
  number = {5},
  pages = {543--552},
  doi = {10.1093/labmed/lmae013}
}
Kostenlos starten →